Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Tasmar
Tasmar 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-086561 · Präparat HOS-083306
Catechols and other drugs metabolised by catechol-O-methyltransferase (COMT)
Tolcapone may influence the pharmacokinetics of drugs metabolised by COMT. No effects were seen
on the pharmacokinetics of the COMT substrate carbidopa. An interaction was observed with
benserazide, which may lead to increased levels of benserazide and its active metabolite. The magnitude
of the effect was dependent on the dose of benserazide. The plasma concentrations of benserazide
observed after co-administration of tolcapone and benserazide-25 mg/levodopa were still within the
range of values observed with levodopa/benserazide alone. On the other hand, after coadministration of
tolcapone and benserazide-50 mg/levodopa the benserazide plasma concentrations could be increased
above the levels usually observed with levodopa/benserazide alone. The effect of tolcapone on the
pharmacokinetics of other drugs metabolised by COMT such as -methyldopa, dobutamine,
apomorphine, adrenaline and isoprenaline have not been evaluated. The prescriber should be observant
of adverse reactions caused by putative increased plasma levels of these drugs when combined with
Tasmar.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbidopa (HOS-086562) benserazide (HOS-086563) lead (HOS-085592) levodopa (HOS-086559) methyldopa (HOS-086564) dobutamine (HOS-086565) apomorphine (HOS-086566)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage e79962e4782917307a0da569a9c64d5fe16790a76c30db979f6d915f33b0c1f7 · Zeichen 1003–2156 im Abschnitt
Wechselwirkungen · Tasmar
Tasmar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-086592 · Präparat HOS-083306
Catechols and other drugs metabolised by catechol-O-methyltransferase (COMT)
Tolcapone may influence the pharmacokinetics of drugs metabolised by COMT. No effects were seen
on the pharmacokinetics of the COMT substrate carbidopa. An interaction was observed with
benserazide, which may lead to increased levels of benserazide and its active metabolite. The magnitude
of the effect was dependent on the dose of benserazide. The plasma concentrations of benserazide
observed after co-administration of tolcapone and benserazide-25 mg/levodopa were still within the
range of values observed with levodopa/benserazide alone. On the other hand, after coadministration of
tolcapone and benserazide-50 mg/levodopa the benserazide plasma concentrations could be increased
above the levels usually observed with levodopa/benserazide alone. The effect of tolcapone on the
pharmacokinetics of other drugs metabolised by COMT such as -methyldopa, dobutamine,
apomorphine, adrenaline and isoprenaline have not been evaluated. The prescriber should be observant
of adverse reactions caused by putative increased plasma levels of these drugs when combined with
Tasmar.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbidopa (HOS-086562) benserazide (HOS-086563) lead (HOS-085592) levodopa (HOS-086559) methyldopa (HOS-086564) dobutamine (HOS-086565) apomorphine (HOS-086566)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage e79962e4782917307a0da569a9c64d5fe16790a76c30db979f6d915f33b0c1f7 · Zeichen 1003–2156 im Abschnitt
Wechselwirkungen · Comtess
Comtess 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4–5
HOS-087880 · Präparat HOS-083575
4
and selegiline were observed in repeated-dose studies in parkinsonian patients. However, the
experience of the clinical use of entacapone with several medicinal products, including MAO-A
inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine,
maprotiline and venlafaxine, and medicinal products that are metabolised by COMT (e.g. catechol-
structured compounds: rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine,
alpha-methyldopa, apomorphine, and paroxetine) is still limited. Caution should be exercised when
these medicinal products are used concomitantly with entacapone (see also sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): selegiline (HOS-086575) desipramine (HOS-086249) maprotiline (HOS-086572) venlafaxine (HOS-086573) dopamine (HOS-085948) dobutamine (HOS-086565) methyldopa (HOS-086564) apomorphine (HOS-086566) paroxetine (HOS-086246)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-09-18T01:00:00Z · SHA-256 fa3d8879d7f9d8835c303451aba5afa0417c9a42bba423f3f71a40c3f8d94d33 · Passage 3c592197fa296402268e76a507959b26c502f61c3b5567c38fa7d68d94e5d6c3 · Zeichen 418–1090 im Abschnitt
Wechselwirkungen · Comtan
Comtan 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4–5
HOS-087903 · Präparat HOS-083583
4
imipramine or between entacapone and moclobemide. Similarly, no interactions between entacapone
and selegiline were observed in repeated-dose studies in parkinsonian patients. However, the
experience of the clinical use of entacapone with several medicinal products, including MAO-A
inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine,
maprotiline and venlafaxine, and medicinal products that are metabolised by COMT (e.g. catechol-
structured compounds: rimiterol, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine,
alpha-methyldopa, apomorphine, and paroxetine) is still limited. Caution should be exercised when
these medicinal products are used concomitantly with entacapone (see also sections 4.3 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): imipramine (HOS-085907) moclobemide (HOS-087879) selegiline (HOS-086575) desipramine (HOS-086249) maprotiline (HOS-086572) venlafaxine (HOS-086573) rimiterol (HOS-087904) dopamine (HOS-085948) dobutamine (HOS-086565) methyldopa (HOS-086564) apomorphine (HOS-086566) paroxetine (HOS-086246)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T16:36:00Z · SHA-256 5a934525674e083ec4dd9056db2e81d6f6bd7e081e45463e4be2195fdd4c2470 · Passage 607c7c228205279947c9a575e4730f7853ea1c18929afcfc4a48e376ed14e9a1 · Zeichen 322–1089 im Abschnitt
Wechselwirkungen · Aerinaze
Aerinaze 2.5 mg/120 mg modified-release tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-117649 · Präparat HOS-094665
Sympathomimetic medicines reduce the antihypertensive effect of α-methyldopa, mecamylamine,
reserpine, veratrum alkaloids, and guanethidine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methyldopa (HOS-086564) mecamylamine (HOS-117651) reserpine (HOS-088597) guanethidine (HOS-088596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T02:00:00Z · SHA-256 5f8f717272c7b0715f3f3850df32a9fdf827287c0fbb36ceed60bbd0a24f3b53 · Passage f73d096cc22a9498fdee178ad4d1525b0c0c3a17c4b7a0d89f37eee88909b4b2 · Zeichen 2149–2289 im Abschnitt
Wechselwirkungen · Exforge HCT
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 5 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–11
HOS-121626 · Präparat HOS-095405
9
Dantrolene (infusion) In animals, lethal ventricular fibrillation and
cardiovascular collapse are observed in association with
hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is
recommended that the co-administration of calcium
channel blockers such as amlodipine be avoided in
patients susceptible to malignant hyperthermia and in the
management of malignant hyperthermia.
Tacrolimus There is a risk of increased tacrolimus blood levels when
co-administered with amlodipine. In order to avoid
toxicity of tacrolimus, administration of amlodipine in a
patient treated with tacrolimus requires monitoring of
tacrolimus blood levels and dose adjustment of tacrolimus
when appropriate.
Valsartan Non-steroidal anti- NSAIDS can attenuate the antihypertensive effect of both
and HCT inflammatory drugs angiotensin II antagonists and hydrochlorothiazide when
(NSAIDs), including administered simultaneously. Furthermore, concomitant
selective use of Exforge HCT and NSAIDs may lead to worsening
cyclooxygenase-2 of renal function and an increase in serum potassium.
inhibitors (COX-2 Therefore, monitoring of renal function at the beginning of
inhibitors), the treatment is recommended, as well as adequate
acetylsalicylic acid hydration of the patient.
(>3 g/day), and non-
selective NSAIDs
Valsartan Inhibitors of the uptake The results of an in vitro study with human liver tissue
transporter (rifampicin, indicate that valsartan is a substrate of the hepatic uptake
ciclosporin) or efflux transporter OATP1B1 and of the hepatic efflux transporter
transporter (ritonavir) MRP2. Co-administration of inhibitors of the uptake
transporter (rifampicin, ciclosporin) or efflux transporter
(ritonavir) may increase the systemic exposure to
valsartan.
HCT Alcohol, barbiturates Concomitant administration of thiazide diuretics with
or narcotics substances that also have a blood pressure lowering effect
(e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic
hypotension.
Amantadine Thiazides, including hydrochlorothiazide, may increase
the risk of adverse reactions caused by amantadine.
Anticholinergic agents The bioavailability of thiazide-type diuretics may be
and other medicinal increased by anticholinergic agents (e.g. atropine,
products affecting biperiden), apparently due to a decrease in gastrointestinal
gastric motility motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride
may decrease the bioavailability of thiazide-type diuretics.
Antidiabetic agents Thiazides may alter glucose tolerance. Dose adjustment of
(e.g. insulin and oral the antidiabetic medicinal product may be necessary.
antidiabetic agents)
− Metformin Metformin should be used with caution because of the risk
of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.
Beta blockers and Concomitant use of thiazide diuretics, including
diazoxide hydrochlorothiazide, with beta blockers may increase the
risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic
effect of diazoxide.
Ciclosporin Concomitant treatment with ciclosporin may increase the
risk of hyperuricaemia and gout-type complications.
10
Cytotoxic agents Thiazides, including hydrochlorothiazide, may reduce the
renal excretion of cytotoxic agents (e.g.
cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Digitalis glycosides Thiazide-induced hypokalaemia or hypomagnesaemia may
occur as undesirable effects, favouring the onset of
digitalis-induced cardiac arrhythmias.
Iodine contrasting In case of diuretic-induced dehydration, there is an
agents increased risk of acute renal failure, especially with high
doses of iodine products. Patients should be re-hydrated
before the administration.
Ion exchange resins Absorption of thiazide diuretics, including
hydrochlorothiazide, is decreased by cholestyramine or
colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of
hydrochlorothiazide and resin such that
hydrochlorothiazide is administered at least 4 hours before
or 4-6 hours after the administration of resins would
potentially minimise the interaction.
Medicinal products The hypokalaemic effect of hydrochlorothiazide may be
affecting serum increased by concomitant administration of kaliuretic
potassium level diuretics, corticosteroids, laxatives, adrenocorticotropic
hormone (ACTH), amphotericin, carbenoxolone,
penicillin G and salicylic acid derivatives or
antiarrhythmics. If these medicinal products are to be
prescribed with the amlodipine /valsartan
/hydrochlorothiazide combination, monitoring of
potassium plasma levels is advised.
Medicinal products The hyponatraemic effect of diuretics may be intensified
affecting serum sodium by concomitant administration of medicinal products such
level as antidepressants, antipsychotics, antiepileptics, etc.
Caution is indicated in long-term administration of these
medicinal products.
Medicinal products that Due to the risk of hypokalaemia, hydrochlorothiazide
could induce torsades should be administered with caution when associated with
de pointes medicinal products that could induce torsades de pointes,
in particular Class Ia and Class III antiarrhythmics and
some antipsychotics.
Medicinal products Dose adjustment of uricosuric medicinal products may be
used in the treatment of necessary as hydrochlorothiazide may raise the level of
gout (probenecid, serum uric acid. Increase of dose of probenecid or
sulfinpyrazone and sulfinpyrazone may be necessary.
allopurinol) Co-administration of thiazide diuretics, including
hydrochlorothiazide, may increase the incidence of
hypersensitivity reactions to allopurinol.
Methyldopa There have been isolated reports of haemolytic anaemia
occurring with concomitant use of hydrochlorothiazide
and methyldopa.
Non-depolarising Thiazides, including hydrochlorothiazide, potentiate the
skeletal muscle action of curare derivatives.
relaxants (e.g.
tubocurarine)
Other anti-hypertensive Thiazides potentiate the antihypertensive action of other
medicinal products antihypertensive drugs (e.g. guanethidine, methyldopa,
beta-blockers, vasodilators, calcium channel blockers,
ACE inhibitors, ARBs and Direct Renin Inhibitors
[DRIs]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) lead (HOS-085592) potassium (HOS-086929) ritonavir (HOS-084521) amantadine (HOS-086615) atropine (HOS-089182) biperiden (HOS-085953) cisapride (HOS-085610) glucose (HOS-088412) metformin (HOS-091032) diazoxide (HOS-088588) cyclophosphamide (HOS-084539) methotrexate (HOS-087522) iodine (HOS-087479) colestipol (HOS-089168) amphotericin (HOS-088524) carbenoxolone (HOS-089156) penicillin G (HOS-121627) salicylic acid (HOS-088803) sodium (HOS-109681) probenecid (HOS-085208) uric acid (HOS-089176) sulfinpyrazone (HOS-089177) allopurinol (HOS-089178) methyldopa (HOS-086564) tubocurarine (HOS-089174) guanethidine (HOS-088596) dantrolene (HOS-109261) verapamil (HOS-090602) calcium (HOS-085615) tacrolimus (HOS-085202)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T15:33:00Z · SHA-256 2096581c7b0afb2c48317340c55eeef559ee192a2bef927e9adeba55285d5694 · Passage 61bbc187393dbf47a0e8f64a7f5fde78d30721577fc88477dbb1075c82d35601 · Zeichen 4434–13491 im Abschnitt
Wechselwirkungen · Copalia HCT
Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 5 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–11
HOS-122667 · Präparat HOS-095555
9
Dantrolene (infusion) In animals, lethal ventricular fibrillation and
cardiovascular collapse are observed in association with
hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is
recommended that the co-administration of calcium
channel blockers such as amlodipine be avoided in
patients susceptible to malignant hyperthermia and in the
management of malignant hyperthermia.
Tacrolimus There is a risk of increased tacrolimus blood levels when
co-administered with amlodipine. In order to avoid
toxicity of tacrolimus, administration of amlodipine in a
patient treated with tacrolimus requires monitoring of
tacrolimus blood levels and dose adjustment of tacrolimus
when appropriate.
Valsartan Non-steroidal anti- NSAIDS can attenuate the antihypertensive effect of both
and HCT inflammatory drugs angiotensin II antagonists and hydrochlorothiazide when
(NSAIDs), including administered simultaneously. Furthermore, concomitant
selective use of Copalia HCT and NSAIDs may lead to worsening
cyclooxygenase-2 of renal function and an increase in serum potassium.
inhibitors (COX-2 Therefore, monitoring of renal function at the beginning of
inhibitors), the treatment is recommended, as well as adequate
acetylsalicylic acid hydration of the patient.
(>3 g/day), and non-
selective NSAIDs
Valsartan Inhibitors of the uptake The results of an in vitro study with human liver tissue
transporter (rifampicin, indicate that valsartan is a substrate of the hepatic uptake
ciclosporin) or efflux transporter OATP1B1 and of the hepatic efflux transporter
transporter (ritonavir) MRP2. Co-administration of inhibitors of the uptake
transporter (rifampicin, ciclosporin) or efflux transporter
(ritonavir) may increase the systemic exposure to
valsartan.
HCT Alcohol, barbiturates Concomitant administration of thiazide diuretics with
or narcotics substances that also have a blood pressure lowering effect
(e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic
hypotension.
Amantadine Thiazides, including hydrochlorothiazide, may increase
the risk of adverse reactions caused by amantadine.
Anticholinergic agents The bioavailability of thiazide-type diuretics may be
and other medicinal increased by anticholinergic agents (e.g. atropine,
products affecting biperiden), apparently due to a decrease in gastrointestinal
gastric motility motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride
may decrease the bioavailability of thiazide-type diuretics.
Antidiabetic agents Thiazides may alter glucose tolerance. Dose adjustment of
(e.g. insulin and oral the antidiabetic medicinal product may be necessary.
antidiabetic agents)
− Metformin Metformin should be used with caution because of the risk
of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.
Beta blockers and Concomitant use of thiazide diuretics, including
diazoxide hydrochlorothiazide, with beta blockers may increase the
risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic
effect of diazoxide.
Ciclosporin Concomitant treatment with ciclosporin may increase the
risk of hyperuricaemia and gout-type complications.
10
Cytotoxic agents Thiazides, including hydrochlorothiazide, may reduce the
renal excretion of cytotoxic agents (e.g.
cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Digitalis glycosides Thiazide-induced hypokalaemia or hypomagnesaemia may
occur as undesirable effects, favouring the onset of
digitalis-induced cardiac arrhythmias.
Iodine contrasting In case of diuretic-induced dehydration, there is an
agents increased risk of acute renal failure, especially with high
doses of iodine products. Patients should be re-hydrated
before the administration.
Ion exchange resins Absorption of thiazide diuretics, including
hydrochlorothiazide, is decreased by cholestyramine or
colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of
hydrochlorothiazide and resin such that
hydrochlorothiazide is administered at least 4 hours before
or 4-6 hours after the administration of resins would
potentially minimise the interaction.
Medicinal products The hypokalaemic effect of hydrochlorothiazide may be
affecting serum increased by concomitant administration of kaliuretic
potassium level diuretics, corticosteroids, laxatives, adrenocorticotropic
hormone (ACTH), amphotericin, carbenoxolone,
penicillin G and salicylic acid derivatives or
antiarrhythmics. If these medicinal products are to be
prescribed with the amlodipine /valsartan
/hydrochlorothiazide combination, monitoring of
potassium plasma levels is advised.
Medicinal products The hyponatraemic effect of diuretics may be intensified
affecting serum sodium by concomitant administration of medicinal products such
level as antidepressants, antipsychotics, antiepileptics, etc.
Caution is indicated in long-term administration of these
medicinal products.
Medicinal products that Due to the risk of hypokalaemia, hydrochlorothiazide
could induce torsades should be administered with caution when associated with
de pointes medicinal products that could induce torsades de pointes,
in particular Class Ia and Class III antiarrhythmics and
some antipsychotics.
Medicinal products Dose adjustment of uricosuric medicinal products may be
used in the treatment of necessary as hydrochlorothiazide may raise the level of
gout (probenecid, serum uric acid. Increase of dose of probenecid or
sulfinpyrazone and sulfinpyrazone may be necessary.
allopurinol) Co-administration of thiazide diuretics, including
hydrochlorothiazide, may increase the incidence of
hypersensitivity reactions to allopurinol.
Methyldopa There have been isolated reports of haemolytic anaemia
occurring with concomitant use of hydrochlorothiazide
and methyldopa.
Non-depolarising Thiazides, including hydrochlorothiazide, potentiate the
skeletal muscle action of curare derivatives.
relaxants (e.g.
tubocurarine)
Other anti-hypertensive Thiazides potentiate the antihypertensive action of other
medicinal products antihypertensive drugs (e.g. guanethidine, methyldopa,
beta-blockers, vasodilators, calcium channel blockers,
ACE inhibitors, ARBs and Direct Renin Inhibitors
[DRIs]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amphotericin (HOS-088524) iodine (HOS-087479) colestipol (HOS-089168) diazoxide (HOS-088588) cyclophosphamide (HOS-084539) methotrexate (HOS-087522) dantrolene (HOS-109261) verapamil (HOS-090602) calcium (HOS-085615) tacrolimus (HOS-085202) angiotensin II (HOS-085480) lead (HOS-085592) potassium (HOS-086929) ritonavir (HOS-084521) amantadine (HOS-086615) atropine (HOS-089182) biperiden (HOS-085953) cisapride (HOS-085610) glucose (HOS-088412) metformin (HOS-091032) carbenoxolone (HOS-089156) penicillin G (HOS-121627) salicylic acid (HOS-088803) sodium (HOS-109681) probenecid (HOS-085208) uric acid (HOS-089176) sulfinpyrazone (HOS-089177) allopurinol (HOS-089178) methyldopa (HOS-086564) tubocurarine (HOS-089174) guanethidine (HOS-088596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T11:21:00Z · SHA-256 230f24622c23683c6a46653c5bf6b1c68bc72aa3359d9f8eed8a17a080938906 · Passage 131d80a8b0eaa19356ee9d14064b9ff9cbc55b6c5f27c3883f1f818096746a3b · Zeichen 4434–13492 im Abschnitt
Wechselwirkungen · Dafiro HCT
Dafiro HCT 5 mg/160 mg/12.5 mg film-coated tablets Dafiro HCT 10 mg/160 mg/12.5 mg film-coated tablets Dafiro HCT 5 mg/160 mg/25 mg film-coated tablets Dafiro HCT 10 mg/160 mg/25 mg film-coated tablets Dafiro HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–11
HOS-122720 · Präparat HOS-095563
9
Dantrolene (infusion) In animals, lethal ventricular fibrillation and
cardiovascular collapse are observed in association with
hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is
recommended that the co-administration of calcium
channel blockers such as amlodipine be avoided in
patients susceptible to malignant hyperthermia and in the
management of malignant hyperthermia.
Tacrolimus There is a risk of increased tacrolimus blood levels when
co-administered with amlodipine. In order to avoid
toxicity of tacrolimus, administration of amlodipine in a
patient treated with tacrolimus requires monitoring of
tacrolimus blood levels and dose adjustment of tacrolimus
when appropriate.
Valsartan Non-steroidal anti- NSAIDS can attenuate the antihypertensive effect of both
and HCT inflammatory drugs angiotensin II antagonists and hydrochlorothiazide when
(NSAIDs), including administered simultaneously. Furthermore, concomitant
selective use of Dafiro HCT and NSAIDs may lead to worsening of
cyclooxygenase-2 renal function and an increase in serum potassium.
inhibitors (COX-2 Therefore, monitoring of renal function at the beginning of
inhibitors), the treatment is recommended, as well as adequate
acetylsalicylic acid hydration of the patient.
(>3 g/day), and non-
selective NSAIDs
Valsartan Inhibitors of the uptake The results of an in vitro study with human liver tissue
transporter (rifampicin, indicate that valsartan is a substrate of the hepatic uptake
ciclosporin) or efflux transporter OATP1B1 and of the hepatic efflux transporter
transporter (ritonavir) MRP2. Co-administration of inhibitors of the uptake
transporter (rifampicin, ciclosporin) or efflux transporter
(ritonavir) may increase the systemic exposure to
valsartan.
HCT Alcohol, barbiturates Concomitant administration of thiazide diuretics with
or narcotics substances that also have a blood pressure lowering effect
(e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic
hypotension.
Amantadine Thiazides, including hydrochlorothiazide, may increase
the risk of adverse reactions caused by amantadine.
Anticholinergic agents The bioavailability of thiazide-type diuretics may be
and other medicinal increased by anticholinergic agents (e.g. atropine,
products affecting biperiden), apparently due to a decrease in gastrointestinal
gastric motility motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride
may decrease the bioavailability of thiazide-type diuretics.
Antidiabetic agents Thiazides may alter glucose tolerance. Dose adjustment of
(e.g. insulin and oral the antidiabetic medicinal product may be necessary.
antidiabetic agents)
− Metformin Metformin should be used with caution because of the risk
of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.
Beta blockers and Concomitant use of thiazide diuretics, including
diazoxide hydrochlorothiazide, with beta blockers may increase the
risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic
effect of diazoxide.
Ciclosporin Concomitant treatment with ciclosporin may increase the
risk of hyperuricaemia and gout-type complications.
10
Cytotoxic agents Thiazides, including hydrochlorothiazide, may reduce the
renal excretion of cytotoxic agents (e.g.
cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Digitalis glycosides Thiazide-induced hypokalaemia or hypomagnesaemia may
occur as undesirable effects, favouring the onset of
digitalis-induced cardiac arrhythmias.
Iodine contrasting In case of diuretic-induced dehydration, there is an
agents increased risk of acute renal failure, especially with high
doses of iodine products. Patients should be re-hydrated
before the administration.
Ion exchange resins Absorption of thiazide diuretics, including
hydrochlorothiazide, is decreased by cholestyramine or
colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of
hydrochlorothiazide and resin such that
hydrochlorothiazide is administered at least 4 hours before
or 4-6 hours after the administration of resins would
potentially minimise the interaction.
Medicinal products The hypokalaemic effect of hydrochlorothiazide may be
affecting serum increased by concomitant administration of kaliuretic
potassium level diuretics, corticosteroids, laxatives, adrenocorticotropic
hormone (ACTH), amphotericin, carbenoxolone,
penicillin G and salicylic acid derivatives or
antiarrhythmics. If these medicinal products are to be
prescribed with the amlodipine /valsartan
/hydrochlorothiazide combination, monitoring of
potassium plasma levels is advised.
Medicinal products The hyponatraemic effect of diuretics may be intensified
affecting serum sodium by concomitant administration of medicinal products such
level as antidepressants, antipsychotics, antiepileptics, etc.
Caution is indicated in long-term administration of these
medicinal products.
Medicinal products that Due to the risk of hypokalaemia, hydrochlorothiazide
could induce torsades should be administered with caution when associated with
de pointes medicinal products that could induce torsades de pointes,
in particular Class Ia and Class III antiarrhythmics and
some antipsychotics.
Medicinal products Dose adjustment of uricosuric medicinal products may be
used in the treatment of necessary as hydrochlorothiazide may raise the level of
gout (probenecid, serum uric acid. Increase of dose of probenecid or
sulfinpyrazone and sulfinpyrazone may be necessary.
allopurinol) Co-administration of thiazide diuretics, including
hydrochlorothiazide, may increase the incidence of
hypersensitivity reactions to allopurinol.
Methyldopa There have been isolated reports of haemolytic anaemia
occurring with concomitant use of hydrochlorothiazide
and methyldopa.
Non-depolarising Thiazides, including hydrochlorothiazide, potentiate the
skeletal muscle action of curare derivatives.
relaxants (e.g.
tubocurarine)
Other anti-hypertensive Thiazides potentiate the antihypertensive action of other
medicinal products antihypertensive drugs (e.g. guanethidine, methyldopa,
beta-blockers, vasodilators, calcium channel blockers,
ACE inhibitors, ARBs and Direct Renin Inhibitors
[DRIs]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dantrolene (HOS-109261) verapamil (HOS-090602) calcium (HOS-085615) tacrolimus (HOS-085202) angiotensin II (HOS-085480) lead (HOS-085592) potassium (HOS-086929) ritonavir (HOS-084521) amantadine (HOS-086615) atropine (HOS-089182) biperiden (HOS-085953) cisapride (HOS-085610) glucose (HOS-088412) metformin (HOS-091032) diazoxide (HOS-088588) cyclophosphamide (HOS-084539) methotrexate (HOS-087522) iodine (HOS-087479) colestipol (HOS-089168) amphotericin (HOS-088524) carbenoxolone (HOS-089156) penicillin G (HOS-121627) salicylic acid (HOS-088803) sodium (HOS-109681) probenecid (HOS-085208) uric acid (HOS-089176) sulfinpyrazone (HOS-089177) allopurinol (HOS-089178) methyldopa (HOS-086564) tubocurarine (HOS-089174) guanethidine (HOS-088596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T17:50:00Z · SHA-256 ac895b922284b71e7c5c23e23c9993c138af1676fdc3c53bcfaa54fe9f7593a7 · Passage 97d44e9311b10ee812c39d023fdb8dcc2cc4eb2fbbe2ddb1ce622654982ed958 · Zeichen 4412–13469 im Abschnitt
Wechselwirkungen · Feraccru
Feraccru 30 mg hard capsules · Abschnitt 4.5 · PDF-Seite 4
HOS-128848 · Präparat HOS-096637
Concomitant use of iron with methyldopa may antagonise the hypotensive effect of methyldopa (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): iron (HOS-085656) methyldopa (HOS-086564)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-25T15:59:00Z · SHA-256 b2d699d0ce35a74de8558e02a2453b5b268ff8751bf546e8905e41445f10e069 · Passage c51df8be082e382aebf1549dfc5e940f1f6932b92e3c0ba41540ffd84f53c446 · Zeichen 1664–1774 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.